Celiste, Zia .
HRN: 26-52-99 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/27/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/27/2025
02/03/2025
IVT
45mg
Q24
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes